Kura Oncology ((KURA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kura Oncology is conducting a Phase 1 clinical study titled Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors. The study aims to assess the safety and effectiveness of KO-2806, a farnesyl transferase inhibitor, in treating advanced solid tumors. This research is significant as it explores new treatment avenues for patients with limited options.
The study is testing KO-2806, known as Darlifarnib, both as a standalone treatment and in combination with other drugs like Cabozantinib and Adagrasib. These interventions are designed to target specific genetic mutations in various cancers, including non-small cell lung cancer and colorectal cancer.
The study follows a non-randomized, sequential intervention model with no masking. Its primary purpose is treatment-focused, aiming to evaluate the drug’s potential in real-world scenarios.
The study began on August 17, 2023, and is currently recruiting participants. The last update was recorded on October 8, 2025. These dates are crucial as they mark the study’s progress and potential timeline for results.
This update could influence Kura Oncology’s stock performance positively, as successful trials may lead to new market opportunities. Investors should also consider the competitive landscape, as other companies like Mirati Therapeutics are involved in similar research.
The study is ongoing, with further details available on the ClinicalTrials portal.